A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)

PHASE3CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

October 12, 2021

Primary Completion Date

July 26, 2022

Study Completion Date

July 26, 2022

Conditions
Cystic Fibrosis
Interventions
DRUG

ELX/TEZ/IVA

Fixed dose combination (FDC) tablet for oral administration.

DRUG

IVA

Tablet for oral administration.

Trial Locations (19)

Unknown

Royal Adelaide Hospital, Adelaide

The Prince Charles Hospital, Chermside

Alfred Hospital, Melbourne, VIC

Institute for Respiratory Health, Nedlands

Telethon Kids Institute, Nedlands

The Royal Children's Hospital, Parkville, VIC

Mater Adult Hospital, South Brisbane

Queensland Children's Hospital, South Brisbane

Cliniques Universitaires de Bruxelles Hopital Erasme, Brussels

Universitair Ziekenhuis Brussel - Campus Jette, Brussels

Universitair Ziekenhuis Gent, Ghent

Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven

University of Calgary Medical Clinic of the Foothills Medical Centre, Calgary

University of Alberta Hospital, Edmonton Clinic, Edmonton

Queen Elizabeth II Health Sciences Center, Halifax

Hospital Universitari Vall d Hebron, Barcelona

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario Ramon y Cajal, Madrid

Corporacio Sanitaria Parc Tauli - Sabadell Hospital Universitari, Sabadell

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT04969224 - A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF) | Biotech Hunter | Biotech Hunter